Mitsubishi UFJ Asset Management Portfolio holdings
AUM
$125B
1-Year Return
23.89%
This Quarter Return
+8.91%
1 Year Return
+23.89%
3 Year Return
+93.04%
5 Year Return
+163.06%
10 Year Return
+400.91%
AUM
$47.9B
AUM Growth
+$5.83B
(+14%)
Cap. Flow
+$2.66B
Cap. Flow
% of AUM
5.56%
Top 10 Holdings %
Top 10 Hldgs %
27.7%
Holding
1,160
New
43
Increased
790
Reduced
196
Closed
50
Top Buys
| 1 |
Arthur J. Gallagher & Co
AJG
|
$249M |
| 2 |
Apple
AAPL
|
$162M |
| 3 |
Accenture
ACN
|
$136M |
| 4 |
IQVIA
IQV
|
$109M |
| 5 |
Thermo Fisher Scientific
TMO
|
$82.6M |
Top Sells
| 1 |
Medtronic
MDT
|
$244M |
| 2 |
Baxter International
BAX
|
$154M |
| 3 |
Adobe
ADBE
|
$97.6M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
$71.6M |
| 5 |
Microsoft
MSFT
|
$59.8M |
Sector Composition
| 1 | Technology | 29.5% |
| 2 | Healthcare | 16.05% |
| 3 | Financials | 13.31% |
| 4 | Consumer Discretionary | 8.72% |
| 5 | Industrials | 7.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Avidity Biosciences
RNA
$6.48B
| $267K | ﹤0.01% |
24,109
+1,108
| +5% | +$12.3K |
|
1002
Vir Biotechnology
VIR
$732M
| $265K | ﹤0.01% |
10,807
+857
| +9% | +$21K |
|
1003
BioNTech
BNTX
$27B
| $264K | ﹤0.01% |
2,446
+821
| +51% | +$88.6K |
|
1004
4D Molecular Therapeutics
FDMT
$340M
| $261K | ﹤0.01% |
14,458
+2,422
| +20% | +$43.8K |
|
1005
GDS Holdings
GDS
$6.35B
| $254K | ﹤0.01% |
23,100
-30,300
| -57% | -$333K |
|
1006
Beam Therapeutics
BEAM
$2.11B
| $253K | ﹤0.01% |
+7,931
| New | +$253K |
|
1007
Ultragenyx Pharmaceutical
RARE
$3.07B
| $253K | ﹤0.01% |
5,489
-2,328
| -30% | -$107K |
|
1008
Intellia Therapeutics
NTLA
$1.29B
| $253K | ﹤0.01% |
6,200
+647
| +12% | +$26.4K |
|
1009
BridgeBio Pharma
BBIO
$10.2B
| $251K | ﹤0.01% |
14,569
-6,474
| -31% | -$111K |
|
|
ONL
1010
Orion Office REIT
ONL
$170M
| $250K | ﹤0.01% |
37,889
+11,070
| +41% | +$73.2K |
|
1011
Iovance Biotherapeutics
IOVA
$901M
| $249K | ﹤0.01% |
35,428
-7,161
| -17% | -$50.4K |
|
1012
Fate Therapeutics
FATE
$116M
| $249K | ﹤0.01% |
52,383
+39,734
| +314% | +$189K |
|
1013
Xencor
XNCR
$610M
| $249K | ﹤0.01% |
9,978
+296
| +3% | +$7.39K |
|
1014
Forum Energy Technologies
FET
$309M
| $248K | ﹤0.01% |
+9,704
| New | +$248K |
|
1015
Rocket Pharmaceuticals
RCKT
$354M
| $248K | ﹤0.01% |
12,496
-3,896
| -24% | -$77.4K |
|
1016
CRISPR Therapeutics
CRSP
$4.99B
| $247K | ﹤0.01% |
4,408
-272
| -6% | -$15.3K |
|
1017
Upstart Holdings
UPST
$6.44B
| $244K | ﹤0.01% |
6,822
-2,887
| -30% | -$103K |
|
|
TSVT
1018
DELISTED
2seventy bio
TSVT
| $243K | ﹤0.01% |
23,981
+6,722
| +39% | +$68K |
|
1019
Editas Medicine
EDIT
$248M
| $242K | ﹤0.01% |
29,387
+4,678
| +19% | +$38.5K |
|
1020
Maravai LifeSciences
MRVI
$363M
| $242K | ﹤0.01% |
19,449
+815
| +4% | +$10.1K |
|
|
BLUE
1021
DELISTED
bluebird bio
BLUE
| $241K | ﹤0.01% |
3,662
+1,766
| +93% | +$116K |
|
1022
Recursion Pharmaceuticals
RXRX
$2.01B
| $232K | ﹤0.01% |
31,064
+10,285
| +49% | +$76.8K |
|
1023
dLocal
DLO
$3.94B
| $226K | ﹤0.01% |
18,542
+3,832
| +26% | +$46.8K |
|
1024
AbCellera Biologics
ABCL
$1.26B
| $221K | ﹤0.01% |
34,214
+19,083
| +126% | +$123K |
|
1025
Riot Platforms
RIOT
$4.91B
| $221K | ﹤0.01% |
18,666
-22,593
| -55% | -$267K |
|